Ottimo Pharma, a NYC-based private biotech company, raised over $140M in funding.
The round was led by OrbiMed, Avoro Capital, Samsara BioCapital. Other investors included RTW Investments, Decheng Capital, Janus Henderson Investors, J.P. Morgan Life Sciences Private Capital, Invus, and founding investor Medicxi.
In connection with the financing Peter Thompson (OrbiMed), Mark Chin (Avoro Capital), and Srini Akkaraju (Samsara BioCapital) will join the Board of Directors.
The company intends to use the funds to accelerate the lead asset, Jankistomig, a first-in-class PD1/VEGFR2 bifunctional antibody for multiple solid tumor indications, in both IV and SC forms as well as a pipeline of follow-on bifunctional assets.
Founded by Medicxi and Jonny Finlay and led by CEO David Epstein, Ottimo Pharma is a biotechnology company focused on the development of cancer therapies for solid tumors. its lead asset, Jankistomig, is a PD1/VEGFR2 bifunctional antibody designed as a dual pathway, biparatopic single-agent IgG therapy, targeting both immune checkpoint inhibition and angiogenesis in the treatment of cancer. By advancing this dual-pathway approach, it aims to offer a wider therapeutic window, improve cancer treatment outcomes and reduce the overall healthcare burden.
Ottimo anticipates filing of its first IND in late 2025.
FinSMEs
19/12/2024